Trevi Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 20, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 20, 2024
TRVI$14.33+11.9%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(Amounts in thousands, except share amounts)
| Common Stock · AdditionalPaid- · Accumulated Other Comprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | in Capital | Loss | Deficit | Equity | |
| Balance at December 31, 2021 | 28,505,804 | $29 | $197,963 | $— | $(180,917) | $17,075 |
| Stock-based compensation | — | — | 2,327 | — | — | 2,327 |
| Issuance of common stock from exercise of stock options | 51,005 | — | 139 | — | — | 139 |
| Issuance of common stock from Employee Stock Purchase Plan | 54,457 | — | 56 | — | — | 56 |
| Issuance of common stock under the at-the-market sales agreement, net of commissions and allocated fees | — | — | (42) | — | — | (42) |
| Issuance of common stock and warrants under public offering and private placement, less issuance costs | 20,433,624 | 20 | 105,375 | — | — | 105,395 |
| Issuance of common stock from warrant exercise | 10,898,540 | 11 | 11,772 | — | — | 11,783 |
| Unrealized losses on available-for-sale marketable securities | — | — | — | (122) | — | (122) |
| Net loss | — | — | — | — | (29,152) | (29,152) |
| Balance at December 31, 2022 | 59,943,430 | $60 | $317,590 | $(122) | $(210,069) | $107,459 |
| Stock-based compensation | — | — | 2,247 | — | — | 2,247 |
| Issuance of common stock from exercise of stock options | 146,081 | — | 74 | — | — | 74 |
| Issuance of common stock from Employee Stock Purchase Plan | 50,091 | — | 68 | — | — | 68 |
| Issuance of common stock under the at-the-market sales agreement, net of commissions and allocated fees | 750,000 | 1 | 1,670 | — | — | 1,671 |
| Issuance of common stock from pre-funded warrant exercise | 7,394,097 | 7 | (7) | — | — | — |
| Unrealized gains on available-for-sale marketable securities | — | — | — | 93 | — | 93 |
| Net loss | — | — | — | — | (29,065) | (29,065) |
| Balance at December 31, 2023 | 68,283,699 | $68 | $321,642 | $(29) | $(239,134) | $82,547 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.